483
ABC PharmaceuticalsABC Pharmaceuticals – FDA 483, Feb 27, 2025
Record Details
Revance Therapeutics Inc. in Newark, CA, was inspected by the FDA from February 19-27, 2025. The inspection revealed a significant deficiency in laboratory controls, specifically regarding bacterial endotoxin testing procedures. The firm's SOP lacked instructions for sample mixing, and samples were improperly collected and stored, indicating a failure to ensure product quality and purity.
View Company Profile
ID · de22bb22-e4de-4192-adbc-cc975ed8c2f1
Other documents for ABC Pharmaceuticals
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.